Is chloroquine phosphate an oxytetracycline drug?
Apr 15, 2022
Source: Cainiu Health
Dr. Jiang Weimin
Introduction
Chloroquine phosphate is not oxytetracycline. Chloroquine phosphate is a medication used to treat and prevent malaria—a parasitic disease—whereas oxytetracycline is an antibiotic used to treat bacterial infections and belongs to the tetracycline class. Minocycline, like oxytetracycline, is also a tetracycline-class antibiotic; thus, chloroquine phosphate and oxytetracycline are entirely distinct drugs.
Some medications are commonly encountered in daily life, while others are rarely used—such as chloroquine phosphate. Is chloroquine phosphate a tetracycline antibiotic?
Is chloroquine phosphate a tetracycline antibiotic?
Chloroquine phosphate is not a tetracycline antibiotic. It is an antimalarial drug used for both the treatment and prevention of malaria. Malaria is caused by a parasitic infection, whereas tetracycline antibiotics—such as oxytetracycline—are used to treat bacterial infections and belong to the tetracycline class. Minocycline is also a tetracycline-class antibiotic; thus, chloroquine phosphate and tetracyclines are entirely distinct drug classes. During chloroquine phosphate therapy, close monitoring for adverse reactions is essential. Common side effects include myopathy, decreased appetite, diarrhea, and rash; severe adverse reactions may involve visual disturbances, myotoxicity, and even seizures.
Chloroquine phosphate is a relatively older drug indicated for treating chloroquine-sensitive strains of Plasmodium falciparum, P. vivax, and P. malariae. It can be used for suppressive prophylaxis against malaria and for treating extraintestinal amebiasis and certain connective tissue disorders—including photosensitivity-related conditions. As of now, no effective antiviral agent has been identified for the currently prevalent novel coronavirus (SARS-CoV-2) infection; however, several drugs—including chloroquine phosphate—have demonstrated potential therapeutic benefits in clinical studies.
Chloroquine phosphate is primarily administered to adults aged 18–65 years. Individuals with significant risk factors or those exhibiting early signs of severe disease may experience side effects such as headache, dizziness, vertigo, decreased appetite, nausea, and vomiting during chloroquine therapy. We hope this information is helpful to you!
